The stock hasn't moved much and seems to be waiting for triggers. The fall after the earnings has stopped, but the volumes are too low to indicate any reversal. The important supports have held so far, and news flow will determine the movement of the stock. The company has made news for its partnership with Costco for selling its products. Recently the Combat Protein Powder was shipped to Costco stores, and it is likely to be shipped to international locations by the end of next year. The partnership with Costco expands the company's reach beyond specialty health, nutrition and sports stores and online retailers to mass consumer channels. The news about collaboration with Arnold, and the focus on the FitMiss range has also increased hopes about good growth in the topline. In addition to improving the revenues, such collaborations are likely to strengthen of the brand presence of MusclePharm as a company. However, the bottom-line is still negative, and it is important that the company achieves profitability soon. The company has reduced costs, and its recent investment in Biozone Pharmaceuticals (BZNE) is expected to streamline manufacturing operations for its product line. Further, Biozone's QuSome technology can help in lower cost of manufacturing, leading to lower costs. Importantly, the technology improves delivery of nutrients as well as pharmaceuticals to the body, increasing the efficacy at lower doses / amounts. Lower costs can help MusclePharm compete on cost for specific products in specific markets by giving it more room to implement new marketing strategies. Investment and presence of Dr. Phillip Frost in both these companies indicates that there are possible synergies between the two companies. Otherwise, investment of $2 million would not have made sense to Frost. The results of the investment may take time to reflect in the numbers, but the next couple of quarters will indicate the progress being made by the company towards achieving profitability.